2024
How I treat challenging transfusion cases in sickle cell disease
Chou S, Hendrickson J. How I treat challenging transfusion cases in sickle cell disease. Blood 2024 PMID: 38728382, DOI: 10.1182/blood.2023023648.Peer-Reviewed Original ResearchDelayed hemolytic transfusion reactionSickle cell diseaseRed blood cellsTransfusion of red blood cellsRed blood cell alloantibodiesRed blood cell transfusionCell diseaseHemolytic transfusion reactionsManagement of complicationsAlloimmunized patientsRh alloimmunizationCurative therapyTransfusion guidelinesTransfusion recipientsClinical dilemmaFuture transfusionsTransfusionPatient populationTransfusion casesTransfusion reactionsBlood donorsRH variantsBlood cellsAlloimmunizationMedicine providersDecreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource
Ito S, Pandya A, Hauser R, Krishnamurti L, Stites E, Tormey C, Krumholz H, Hendrickson J, Goshua G. Decreasing alloimmunization‐specific mortality in sickle cell disease in the United States: Cost‐effectiveness of a shared transfusion resource. American Journal Of Hematology 2024, 99: 570-576. PMID: 38279581, DOI: 10.1002/ajh.27211.Peer-Reviewed Original ResearchSickle cell diseaseDelayed hemolytic transfusion reactionQuality-adjusted life expectancyAlloimmunized patientsPatient populationRed blood cell alloimmunizationCell diseaseCost-effective interventionMedical expenditure of patientsHealth system perspectiveExpenditure of patientsIncremental cost-effectiveness ratioHemolytic transfusion reactionsUnited StatesMarkov cohort simulationCost-effectiveAverage patient populationCost-effectiveness ratioBirth cohortAnalytical time horizonAntibody historyCohort simulationTransfusionTransfusion reactionsLife expectancy
2023
P‐CB‐21 | RBC Alloimmunization Responder Type and COVID‐19 Vaccine IgG Response in Patients with Sickle Cell Disease
Nakahara H, Cheedarla N, Verkerke H, Cheedarla S, Wu S, Hendrickson J, Roback J, Neish A, Fasano R, Stowell S. P‐CB‐21 | RBC Alloimmunization Responder Type and COVID‐19 Vaccine IgG Response in Patients with Sickle Cell Disease. Transfusion 2023, 63: 159a-160a. DOI: 10.1111/trf.204_17554.Peer-Reviewed Original ResearchEnhanced IgG immune response to COVID‐19 vaccination in patients with sickle cell disease
Nakahara H, Cheedarla N, Verkerke H, Cheedarla S, Wu S, Hendrickson J, Chang A, McLemore M, Rassi F, Roback J, Neish A, Fasano R, Stowell S. Enhanced IgG immune response to COVID‐19 vaccination in patients with sickle cell disease. British Journal Of Haematology 2023, 202: 937-941. PMID: 37287128, PMCID: PMC10751105, DOI: 10.1111/bjh.18899.Peer-Reviewed Original ResearchConceptsSickle cell diseaseCOVID-19 vaccinationAntibody responseCell diseaseSARS-CoV-2 vaccinationIgG immune responseSimilar antibody responsesOptimal vaccination strategyIgG titresIgG responsesVaccination strategiesImmune responseSCD controlsGeneral populationPatientsVaccinationDiseaseResponseCohortTitresEpidemiological and clinical features, therapeutic strategies and outcomes in patients with hyperhaemolysis: A systematic review
Jacobs J, Stephens L, Allen E, Binns T, Booth G, Hendrickson J, Karafin M, Tormey C, Woo J, Adkins B. Epidemiological and clinical features, therapeutic strategies and outcomes in patients with hyperhaemolysis: A systematic review. British Journal Of Haematology 2023, 201: 1025-1032. PMID: 37074146, DOI: 10.1111/bjh.18825.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSickle cell diseaseHyperhaemolysis syndromeAnti-globulin testRed blood cellsSupportive transfusionsIndirect anti-globulin testDirect anti-globulin testIntravenous immune globulinHaemolytic transfusion reactionsImmune globulinMedian hemoglobinClinical featuresCommon therapyUnderlying pathophysiologyTransfusion reactionsCell diseaseSevere formTherapeutic strategiesPatientsSystematic reviewBlood cellsTransfusionHyperhaemolysisDaysCorticosteroids
2022
A US-Wide Red Blood Cell Alloantibody Exchange Can Decrease Mortality and Produce Cost Savings in the Care of Alloimmunized Patients with Sickle Cell Disease
Goshua G, Hauser R, Tormey C, Pandya A, Hendrickson J. A US-Wide Red Blood Cell Alloantibody Exchange Can Decrease Mortality and Produce Cost Savings in the Care of Alloimmunized Patients with Sickle Cell Disease. Blood 2022, 140: 2147-2148. DOI: 10.1182/blood-2022-169099.Peer-Reviewed Original ResearchThe Recipient Epidemiology and Donor Evaluation Study‐IV‐Pediatric (REDS‐IV‐P): A research program striving to improve blood donor safety and optimize transfusion outcomes across the lifespan
Josephson CD, Glynn S, Mathew S, Birch R, Bakkour S, Kreuziger L, Busch MP, Chapman K, Dinardo C, Hendrickson J, Hod EA, Kelly S, Luban N, Mast A, Norris P, Custer B, Sabino E, Sachais B, Spencer BR, Stone M, Kleinman S, for the National Heart L. The Recipient Epidemiology and Donor Evaluation Study‐IV‐Pediatric (REDS‐IV‐P): A research program striving to improve blood donor safety and optimize transfusion outcomes across the lifespan. Transfusion 2022, 62: 982-999. PMID: 35441384, PMCID: PMC9353062, DOI: 10.1111/trf.16869.Peer-Reviewed Original ResearchConceptsBlood safety issueRecipient outcomesData Coordinating CenterRecipient EpidemiologySevere acute respiratory syndrome corona virus 2Blood donor safetyNon-transfused patientsProspective observational studyHospital electronic medical recordsCorona virus 2Sickle cell diseaseElectronic medical recordsPreterm infantsDonor safetyNational HeartMedical recordsBlood donorsCell diseaseObservational studyBlood supplyTransfusion outcomesBlood centersStudy designSpecial populationsCoordinating Center
2021
Management of hemolytic transfusion reactions
Hendrickson JE, Fasano RM. Management of hemolytic transfusion reactions. Hematology 2021, 2021: 704-709. PMID: 34889404, PMCID: PMC8791106, DOI: 10.1182/hematology.2021000308.Peer-Reviewed Original ResearchConceptsHemolytic transfusion reactionsRBC alloantibodiesSevere DHTRTransfusion reactionsRed blood cell transfusionDisease-specific risk factorsPathway activationMultiple RBC alloantibodiesBlood cell transfusionSymptoms of painStem cell transplantationSafety of transfusionSickle cell diseaseClassic pathway activationAlternative pathway activationTransfusion avoidanceCell transfusionCurative therapyCell transplantationPatient's hemoglobinRisk factorsTransfusion safetyCell diseaseDHTRHgb AAltered type 1 interferon responses in alloimmunized and nonalloimmunized patients with sickle cell disease
Madany E, Lee J, Halprin C, Seo J, Baca N, Majlessipour F, Hendrickson JE, Pepkowitz SH, Hayes C, Klapper E, Gibb DR. Altered type 1 interferon responses in alloimmunized and nonalloimmunized patients with sickle cell disease. EJHaem 2021, 2: 700-710. PMID: 35128535, PMCID: PMC8813163, DOI: 10.1002/jha2.270.Peer-Reviewed Original ResearchPeripheral blood mononuclear cellsSickle cell diseaseCell diseaseRace-matched healthy controlsType 1 interferon responseFrequency of alloimmunizationNon-alloimmunized patientsBlood mononuclear cellsType 1 interferonExpression of ISGsGene scoreNonalloimmunized patientsRBC alloimmunizationPlasma cytokinesSCD patientsMononuclear cellsHealthy controlsHigh prevalenceBlood leukocytesAlloimmunizationViral immunityPatientsIFNISG expressionInterferon responsePotential Implications of a Type 1 Interferon Gene Signature on COVID-19 Severity and Chronic Inflammation in Sickle Cell Disease
Madany E, Okwan-Duodu D, Balbuena-Merle R, Hendrickson JE, Gibb DR. Potential Implications of a Type 1 Interferon Gene Signature on COVID-19 Severity and Chronic Inflammation in Sickle Cell Disease. Frontiers In Medicine 2021, 8: 679030. PMID: 34368185, PMCID: PMC8339405, DOI: 10.3389/fmed.2021.679030.Peer-Reviewed Original ResearchSickle cell diseaseCOVID-19 severityIFNα/βType 1 interferonCell diseaseSARS-CoV-2 infectionType 1 interferon responseCorona Virus Disease-19 (COVID-19) pandemicCohort of patientsMajority of patientsInterferon gene signatureIFNα/β productionRace-matched controlsDisease-19 pandemicCOVID-19Express elevated levelsMajority of evidenceSCD diseaseSevere sequelaeChronic inflammationFavorable outcomeVariable progressionClinical consequencesGeneral populationPatients
2020
Red blood cell alloimmunization and sickle cell disease: a narrative review on antibody induction
Hendrickson JE. Red blood cell alloimmunization and sickle cell disease: a narrative review on antibody induction. Annals Of Blood 2020, 5: 33-33. PMID: 33554044, PMCID: PMC7861514, DOI: 10.21037/aob-2020-scd-01.Peer-Reviewed Original ResearchSickle cell diseaseRBC alloantibody formationRace-matched controlsAlloantibody formationCell diseaseImmune systemRed blood cell alloimmunizationRed blood cell alloantibodiesWhite blood cell subsetsAntigen variantsFcγ receptor polymorphismsT cell subsetsBlood cell subsetsType 1 interferonFree hemeRBC alloimmunizationRBC alloantibodiesAntibody inductionPlatelet countCell subsetsReceptor polymorphismsHigh prevalenceMurine studiesMurine modelHuman studiesType I Interferon Gene Signature in Peripheral Blood Mononuclear Cells of Sickle Cell Disease Patients and a Connection to RBC Alloimmunization
Madany E, Lee J, Hendrickson J, Gibb D. Type I Interferon Gene Signature in Peripheral Blood Mononuclear Cells of Sickle Cell Disease Patients and a Connection to RBC Alloimmunization. Blood 2020, 136: 26-27. DOI: 10.1182/blood-2020-142935.Peer-Reviewed Original ResearchFrequency of alloimmunizationInterferon Stimulated GenesHigher IFN scoresInterferon gene signatureSS patientsSickle cell patientsIFN scoreSickle cell diseaseSS diseaseHealthy controlsGene signatureRBC alloimmunizationCell patientsCell diseaseType I interferon gene signaturePeripheral blood mononuclear cellsSickle cell disease patientsInflammatory autoimmune diseaseWhole bloodChronic inflammatory stateType 1 IFNBlood mononuclear cellsIFN gene signatureType 1 interferonMyxovirus resistance protein 1A potential association of an interferon gene signature with RBC alloimmunization in sickle cell disease
Madany E, Kadi N, Pandya S, Hendrickson J, Gibb D. A potential association of an interferon gene signature with RBC alloimmunization in sickle cell disease. The Journal Of Immunology 2020, 204: 145.18-145.18. DOI: 10.4049/jimmunol.204.supp.145.18.Peer-Reviewed Original ResearchSickle cell diseaseInterferon-stimulated genesRBC alloimmunizationMore alloantibodiesGene signatureSCD patientsCell diseaseFrequency of alloimmunizationChronic inflammatory stateInterferon gene signatureProduction of alloantibodiesMultiple interferon-stimulated genesType 1 interferonMyxovirus resistance protein 1Resistance protein 1Alloimmunization frequencyCompatible RBCsRBC transfusionInflammatory stateMxA expressionDisease populationTransfusion modelAlloimmunizationPatientsSiglec-1
2019
Baseline Pain in Adults with Sickle Cell Disease Can be Neuropathic or Nociceptive and Outcomes Differ between Pain Types
Curtis S, Forray A, Hendrickson J, Roberts J. Baseline Pain in Adults with Sickle Cell Disease Can be Neuropathic or Nociceptive and Outcomes Differ between Pain Types. Blood 2019, 134: 1028. DOI: 10.1182/blood-2019-129106.Peer-Reviewed Original ResearchSickle cell diseaseNeuropathic pain qualitiesNeuropathic painNociceptive painPain impactBaseline painED usePain qualityWorse sleepOpioid usePain groupChronic painCell diseaseEpisode frequencyOutcomes Measurement Information System (PROMIS) domainsAdult Sickle Cell QualityAverage daily opioid useHigher C-reactive proteinYale-New Haven HospitalHigh ED useWorse clinical outcomesC-reactive proteinDaily opioid useEmergency department useHalf of adultsIncreased Expression of Type 1 Interferon Stimulated Genes in Sickle Cell Disease and a Potential Association with RBC Alloimmunization
Madany E, Kadi N, Pandya S, Hendrickson J, Gibb D. Increased Expression of Type 1 Interferon Stimulated Genes in Sickle Cell Disease and a Potential Association with RBC Alloimmunization. Blood 2019, 134: 716. DOI: 10.1182/blood-2019-124899.Peer-Reviewed Original ResearchSickle cell diseaseFrequency of alloimmunizationSickle cell patientsInterferon Stimulated GenesSS patientsCell diseaseType 1 interferonMore alloantibodiesMxA levelsCell patientsSS diseaseRBC alloimmunizationSiglec-1Gene signatureElevated levelsNon-alloimmunized patientsInflammatory autoimmune diseaseChronic inflammatory stateProduction of alloantibodiesHemolytic transfusion reactionsIFN gene signatureExpression of MxAMann-Whitney U testMean fluorescence intensityMyxovirus resistance protein 1
2018
Elevated Levels of CD64 MFI on Monocyte Subsets Are Associated with a History of Stroke in Sickle Cell Disease
Curtis S, Balbuena-Merle R, Devine L, Zelterman D, Roberts J, Dearborn-Tomazos J, Sansing L, Hendrickson J. Elevated Levels of CD64 MFI on Monocyte Subsets Are Associated with a History of Stroke in Sickle Cell Disease. Blood 2018, 132: 1093. DOI: 10.1182/blood-2018-99-117504.Peer-Reviewed Original ResearchHistory of strokeSickle cell diseaseRole of monocytesIschemic strokeTotal neutrophil countComplete blood countMonocyte subsetsStroke historyNeutrophil countIntermediate monocytesMonocyte subtypesBlood countClassical monocytesCell diseaseFuture stroke riskIschemic stroke historyVaso-occlusive crisisPro-inflammatory monocytesPathophysiology of strokeCause of morbidityMultivariate logistic regressionNon-classical monocytesT-testHigh-affinity receptorStudent's t-testHLA Class I Alloimmunization and Platelet Transfusion Support in HLA-Identical Bone Marrow Transplant for Sickle Cell Disease: A Sickle Transplant Alliance for Research Study
Nickel R, Horan J, Abraham A, Qayed M, Haight A, Luban N, Hendrickson J. HLA Class I Alloimmunization and Platelet Transfusion Support in HLA-Identical Bone Marrow Transplant for Sickle Cell Disease: A Sickle Transplant Alliance for Research Study. Blood 2018, 132: 3816. DOI: 10.1182/blood-2018-99-114116.Peer-Reviewed Original ResearchBone marrow transplantHLA class ISickle cell diseaseHLA-identical bone marrow transplantsMore platelet transfusionsNon-alloimmunized patientsPlatelet transfusion supportPlatelet transfusionsRBC transfusionClass IPositive PRAPre-BMTTransfusion supportPediatric patientsMarrow transplantCell diseaseBone marrowRed blood cell transfusionHepatic sinusoidal obstruction syndromeApheresis platelet transfusionHLA-disparate donorsBlood cell transfusionSinusoidal obstruction syndromePlatelet transfusion requirementsCord blood graftsChapter 4 Common Significant Non-ABO Antibodies and Blood Group Antigen Alloimmunization
Baine I, Hendrickson J, Tormey C. Chapter 4 Common Significant Non-ABO Antibodies and Blood Group Antigen Alloimmunization. 2018, 25-39. DOI: 10.1016/b978-0-323-54458-0.00004-0.ChaptersNon-ABO antibodiesBlood group antibodiesGroup antibodiesCompatible RBC unitsEnd-organ damageHemolytic transfusion reactionsSetting of pregnancyCommon adverse outcomeFormation of alloantibodiesSickle cell diseaseRBC alloimmunizationPregnant patientsOrgan damageMyelodysplastic syndromePregnant womenAdverse outcomesGeneral patientsTransfusion reactionsHemolytic diseaseCell diseaseHigh riskRed blood cell surfaceImmunologic conceptsClinical practiceAlloimmunization
2017
Transfusion Support of the Patient with Sickle Cell Disease Undergoing Transplantation
Hendrickson J, Fasano R. Transfusion Support of the Patient with Sickle Cell Disease Undergoing Transplantation. 2017, 111-136. DOI: 10.1007/978-3-319-62328-3_5.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationSickle cell diseaseRed blood cellsTransfusion supportTransplant physiciansConditioning regimen intensityOptimal transplant outcomesPeri-transplant periodHigher red blood cellStem cell transplantationTransfusion medicine physiciansRegimen intensityUndergoing transplantationPosttransplant periodTransplant outcomesHSCT populationCurative therapyPlatelet transfusionsSCD patientsTransfusion managementCell transplantationTransfusion therapyDonor selectionIron overloadCell disease
2013
Alloimmunization To HLA Class I Antigens But Not H-Y Antigens Is Associated With Transfusion In Children With Sickle Cell Disease
Nickel R, Hendrickson J, Kean L, Yee M, Bray R, Gebel H, Miklos D, Horan J. Alloimmunization To HLA Class I Antigens But Not H-Y Antigens Is Associated With Transfusion In Children With Sickle Cell Disease. Blood 2013, 122: 39. DOI: 10.1182/blood.v122.21.39.39.Peer-Reviewed Original ResearchHematopoietic stem cell transplantMinor histocompatibility antigensHuman leukocyte antigenSickle cell diseaseHLA class I antibodiesClass I human leukocyte antigenClass I antibodiesPediatric SCD patientsRBC transfusionHLA class IGraft rejectionSCD patientsY antigenHLA antibodiesChronic transfusionIgG antibodiesI antibodiesCell diseaseClass I HLA antibodiesHLA class II antibodiesClass II human leukocyte antigenRed blood cell transfusionManagement of SCDClass IHLA-identical transplantation